Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Axes 126 Companies from Biotech Index; Cut Includes Genomics Cos.

NEW YORK, Jan 22 – The Nasdaq said Monday it had slashed the number of companies it would include in its biotechnology index from 202 to 76, including a number of genomics companies that recently raised tens of millions of dollars last year but have since seen their share prices fall.

The change in the index will be effective Tuesday.

Among the genomics companies that will no longer be included in the index are Compugen, DeCode, Gemini Genomics, Informax, Hyseq, Large Scale Biology, Lynx Therapeutics, Rosetta Inpharmatics, and Variagenics.

Most of these companies are now trading at or near their 52-week lows, as the result of a downturn in the market.

In a statement, the Nasdaq said that securities in the index must meet minimum requirements for price, market value, and average daily share volume.

The Nasdaq Biotechnology Index, which was started in 1993, increased 23 percent in 2000.  

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.